Literature DB >> 30414437

Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis.

Jinping Li1, Xuan Wang2, Wanglei Qu3, Jing Wang4, Shi-Wen Jiang5.   

Abstract

BACKGROUND: Endometrial cancer (EC) is common type of gynecologic malignancy affecting a large number of females around the world. While most early stage cases are well managed with a relatively benign prognosis, the late stage cases have poor survival. Among the many biomarkers identified, serum human epididymis protein 4 (HE4) and CA125 are most promising surrogates for EC detection.
METHODS: We performed a meta-analysis to estimate the diagnostic accuracy of HE4 and CA125 and compared their performance. A literature research was performed in Medline, Cochrane Literature Library and CNKI. After filtering, twelve studies evaluating the diagnostic value of serum HE4, alone or in comparison with CA125, were included. The total sample size was 1106 patients and 1480 controls. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio (DOR) were calculated and summary receiver operating characteristic (SROC) curves were plotted to assess the diagnostic accuracy.
RESULTS: The pooled estimates for HE4 were sensitivity: 0.71 (95%CI 0.56-0.82), specificity: 0.87 (95%CI 0.80-0.92), and area under ROC curve: 0.88 (0.85-0.91), compared to 0.35 (95% CI 0.25-0.46), 0.83 (95% CI 0.71-0.91), and 0.58 (95% CI 0.54-0.63), respectively, of CA125. Subgroup analysis demonstrated a better performance of HE4 in Caucasian population, compared to Chinese population.
CONCLUSION: This analysis suggested that when stage and histological type are not specifically considered, serum HE4 is generally a better tool than CA125 in EC diagnosis by its significantly higher sensitivity than CA125.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  CA125; Diagnostic accuracy; Endometrial cancer; HE4; Human epididymis protein 4

Mesh:

Substances:

Year:  2018        PMID: 30414437     DOI: 10.1016/j.cca.2018.11.011

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Clinical value of ROMA index in diagnosis of ovarian cancer: meta-analysis.

Authors:  Ranliang Cui; Yichao Wang; Ying Li; Yueguo Li
Journal:  Cancer Manag Res       Date:  2019-03-28       Impact factor: 3.989

2.  Combination IETA Ultrasonographic Characteristics Simple Scoring Method With Tumor Biomarkers Effectively Improves the Differentiation Ability of Benign and Malignant Lesions in Endometrium and Uterine Cavity.

Authors:  Dongmei Lin; Liang Zhao; Yunxiao Zhu; Yujun Huang; Kun Yuan; Wenfen Liu; Shengli Li; Xia Guo; Yi Hao
Journal:  Front Oncol       Date:  2021-08-30       Impact factor: 6.244

Review 3.  The Role of Human Epididymis Protein 4 in the Diagnosis and Prognosis of Diseases: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies.

Authors:  Ming-Li Sun; Zhi-Yong Yang; Qi-Jun Wu; Yi-Zi Li; Xin-Yu Li; Fang-Hua Liu; Yi-Fan Wei; Zhao-Yan Wen; Bei Lin; Ting-Ting Gong
Journal:  Front Med (Lausanne)       Date:  2022-03-24

4.  Urine CA125 and HE4 for the Triage of Symptomatic Women with Suspected Endometrial Cancer.

Authors:  Kelechi Njoku; Chloe E Barr; Caroline J J Sutton; Emma J Crosbie
Journal:  Cancers (Basel)       Date:  2022-07-06       Impact factor: 6.575

Review 5.  Diagnostic Accuracy of Liquid Biomarkers for the Non-Invasive Diagnosis of Endometrial Cancer: A Systematic Review and Meta-Analysis.

Authors:  Rebecca Karkia; Sarah Wali; Annette Payne; Emmanouil Karteris; Jayanta Chatterjee
Journal:  Cancers (Basel)       Date:  2022-09-25       Impact factor: 6.575

6.  ERRα inhibitor acts as a potential agonist of PPARγ to induce cell apoptosis and inhibit cell proliferation in endometrial cancer.

Authors:  Meimei Huang; Lili Chen; Xiaodan Mao; Guifen Liu; Yuqin Gao; Xiaoqing You; Min Gao; Jalid Sehouli; Pengming Sun
Journal:  Aging (Albany NY)       Date:  2020-11-10       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.